Shortcomings of pediatric clinical trials one of hot topics at AAPS Annual Meeting

October 11, 2001

ARLINGTON, Va. - October 11, 2001 - Scientists from academia, industry, government and other research institutions worldwide will gather at the Colorado Convention Center for the 2001 Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS): "Pharmaceutical Sciences: Climbing New Heights." Dr. Donald Francis, whose efforts to call attention to AIDS were chronicled in the movie "And The Band Played On," will formally kickoff the meeting October 21 at the opening session.

The meeting features roundtable discussions and the presentation of thousands of new scientific research studies. Here is a sampling:

Public's Involvement in Design of Pediatric Trials Sought - With new regulations currently under review regarding pediatric drug clinical trials, the FDA is inviting the public to help ensure that ethical boundaries are observed in the design and implementation of pediatric trials. During a press conference/teleconference on Wednesday, October 24 at 10:30 a.m. EST (9:30 a.m. CST, 8:30 a.m. MST, 7:30 a.m. PST), Steve Hirschfield, M.D., Ph.D., of the FDA will address the current shortcomings of the process and how the public can join Institutional Review Boards. In addition, AAPS will provide tips for parents wanting to enroll their children in a clinical trial. Pharmaceutical scientists and FDA officials will focus on the challenges of pediatric trials in two sessions.

New Weapon Against HIV and STD's - In the U.S., more than one in three adults have an incurable STD. The unavailability of vaccines to combat HIV and STDs has created an urgent need to stop the spread of the infection. Using the same compound currently employed for coating pills, scientists have developed a new product form to be used in cream and sponge form that inactivates HIV and STDs in animals, thereby stopping the transmission of the viruses.

Link Between Liver Damage and Prescription Drugs - Drug-induced liver toxicity, caused by certain drugs or the combination of drugs with other substances such as OTCs, herbal remedies, dietary supplements and alcohol, is the leading cause of acute liver failure. This is a huge concern for consumers and a tremendous financial drain on pharmaceutical companies who are often forced to withdraw drugs from the market after spending millions in R & D. John Senior, M.D., from the FDA Office of Drug Safety will address the reasons behind the growing problem, offer solutions for identifying potentially toxic drugs, and recommend mechanisms to spot problem trends once a drug is available to the consumer.

Detecting Counterfeit Medicines - According to the World Health Organization, more than eight percent of pharmaceuticals imported into the U.S. are counterfeit. Phony drugs can cause dangerous interactions with other drugs, or harm consumers by not delivering the medicines their body needs. Laws passed allowing the importation of prescription medicines from other countries have opened the floodgates to counterfeits and created a rapidly growing problem in the U.S. A new study being presented at the AAPS meeting, made possible by a corroboration of scientists from the London Medicines Control Agency and University of London, will disclose new near-infrared methods that detect counterfeits without damaging the integrity of the medication.

New Vaccination Hope for Fish Farms - With the demand for fish outpacing nature's capacity to put it on the table, fish farms have become a necessity. Currently, almost one quarter of seafood consumed globally is "raised" rather than caught. The U.S. alone sustains a $50 billion seafood industry. Unfortunately, raising large populations of fish in tight quarters can allow for the fast spread of viral infections, forcing the destruction of thousands of valuable fish within days of outbreaks and creating huge financial loses for farmers. Current vaccination methods are antiquated and labor intensive. A new oral vaccine and antibiotic treatment that uses coated fish pellets is an excellent alternative to the current method whereby each fish is injected, by hand, with a vaccine or immersed in treated solutions.
About AAPS PharmSciSM

All abstracts presented at the AAPS Annual Meeting are published in a supplement to AAPS PharmSci (, the organization's peer-reviewed, online journal. AAPS PharmSci offers a forum for the rapid exchange and dissemination of scientific knowledge in the pharmaceutical sciences.

About AAPS

AAPS is a professional, scientific society of more than 11,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS aims to advance science through the open exchange of scientific knowledge, serve as an information resource, and contribute to human health through pharmaceutical research and development. For more information about AAPS, visit AAPS Pharmaceutica at .

American Association of Pharmaceutical Scientists

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to